Publications2023-08-23T10:08:45-04:00

A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma, or alveolar rhabdomyosarcoma

Giselle L. Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael Isakoff, Kevin Bielamowicz, Jacquline Kraveka, Peter Carmeliet, Andy De[...]

Abstract|

A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma or alveolar rhabdomyosarcoma

Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline Kraveka, Peter Carmeliet, Andy De[...]

Abstract|

Feasibility and applicability of molecular guided therapy in high grade glioma/diffuse midline glioma: Results from Beat Childhood Cancer NMTRC-009 Molecular Guided Therapy study

Virginia L. Harrod, MD, PhD, Abhinav B. Nagulapally, MS, Elizabeth C. Lewis, Giselle Saulnier Sholler, MD Feasibility and applicability of molecular guided therapy in high grade glioma/diffuse midline glioma: Results from[...]

Abstract|

The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma

Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park, Giselle Saulnier Sholler, The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell[...]

Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models

Shukla, G.S., S.C. Pero, Y. Sun, L. Mei, F. Zhang, G. Sholler, and D.N. Krag, Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in[...]

Go to Top